Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Venture capital firm providing capital and strategic support to early-stage women's health and female-led life science companies.
Avestria Ventures is an early-stage venture capital firm based in the San Francisco Bay Area that invests in women's health and female-led life science companies. The firm provides equity funding, clinical advisory services, and strategic commercialization mentorship to technology-enabled healthcare startups operating at the Seed and Series A stages. Across its two primary investment vehicles, including Fund I which closed in June 2021 and Fund II which closed in July 2024, the firm has built an active portfolio of more than 20 companies. Notable portfolio investments include Axena Health, Alydia Health, and Midi Health, a virtual care clinic that recently secured a $60 million Series B funding round. The firm has also recorded successful exits, such as the acquisition of portfolio company Uqora by Pharmavite. Avestria Ventures was founded in 2019 by Linda Greub and Corinne Nevinny.
Key people at Avestria Ventures.
Avestria Ventures has 15 tracked investments across 12 companies. The latest tracked deal is $59.0M Series B in Mercy BioAnalytics in September 2025.
Key people at Avestria Ventures.
Avestria Ventures is a venture capital firm specializing in early-stage investments in women's health and female-led life science and healthcare companies. Their mission is to address the significant underfunding and undervaluation of women’s health ventures and female founders by investing in scalable, evidence-based businesses that leverage technology and data to improve healthcare quality, access, and affordability. The firm focuses on conditions that affect women exclusively, disproportionately, or differently from men, extending beyond reproductive health to areas like cardiovascular disease and Alzheimer’s. By targeting these overlooked markets, Avestria Ventures aims to generate both economic returns and social impact, fostering innovation in women’s health and life sciences[1][2][3][6][7].
Founded in the mid-2010s and based in the San Francisco Bay Area, Avestria Ventures was co-founded by Linda Greub, who serves as Managing Partner, alongside other key partners such as Tracy Dooley. The firm’s name combines “invest” with the Sanskrit word for girl/woman, reflecting its core mission to invest in women-led ventures and women’s health. Over time, Avestria has evolved to focus on early-stage companies that demonstrate clinical evidence, sustainable competitive advantages, and clear regulatory and reimbursement pathways. Their portfolio includes a diverse range of companies addressing unmet needs in women’s health and life sciences, with notable milestones such as FDA clearance for Alydia Health’s postpartum hemorrhage device[3][5][6][7].
Avestria Ventures rides the growing trend of recognizing women’s health as a distinct and critical sector within healthcare and life sciences, addressing a historically neglected market. The timing is crucial as healthcare increasingly embraces technology and data-driven solutions, and there is rising awareness of gender disparities in medical research and funding. Market forces such as demographic shifts, increased healthcare spending on women, and policy support for innovation in women’s health create favorable conditions. By investing in female founders and women’s health ventures, Avestria not only fills a funding gap but also influences the broader ecosystem by validating and accelerating innovations that improve outcomes for women globally[3][6][7].
Looking ahead, Avestria Ventures is poised to expand its impact with subsequent funds building on the momentum of its initial successes. Trends shaping their journey include the increasing integration of AI and digital health in women’s healthcare, growing patient empowerment, and a broader push for diversity and inclusion in venture capital. As awareness of women’s health disparities grows, Avestria’s role as a specialized investor will likely deepen, potentially influencing larger VC firms to increase their focus on this sector. Their continued support for female-led ventures will be critical in driving innovation and improving healthcare outcomes for women worldwide[5][6][7].
